Search results for "randomized"

showing 10 items of 2323 documents

Effectiveness of a home exercise programme in low back pain: a randomized five-year follow-up study

2007

Background and Purpose. Therapeutic exercise has been shown to be beneficial in decreasing pain and in increasing functioning in patients with chronic low back pain. However, longitudinal follow-up studies are small in number, and often limited in the numbers of subjects due to drop-outs. In addition there is a shortage of real control groups in most cases. The purpose of the present study was to describe long-term changes in intensity of low back pain and in functioning for two study groups five years after undertaking a home exercise programme. Method. This was a randomized follow-up study over five years. Fifty-seven subjects were reassessed with questionnaires five years after their ini…

medicine.medical_specialtybusiness.industryConfoundingFive year follow upPhysical Therapy Sports Therapy and RehabilitationHome exercise programmeLow back painOswestry Disability Indexlaw.inventionPhysical medicine and rehabilitationRandomized controlled triallawmedicineHome exercisePhysical therapyAnalysis of variancemedicine.symptombusinessPhysiotherapy Research International
researchProduct

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

2021

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes includ…

medicine.medical_specialtybusiness.industryContext (language use)Brivaracetammedicine.diseaseDiscontinuationlaw.inventionPsychiatry and Mental healthEpilepsyRandomized controlled trialTolerabilityfocal epilepsy add-on therapy seizurelawConcomitantInternal medicineMedicinePharmacology (medical)Neurology (clinical)LevetiracetamOriginal Research Articlebusinessmedicine.drug
researchProduct

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regime…

2013

Abstract Background:  Interleukin-17A has major proinflammatory activity in psoriatic lesional skin. Objectives:  Assess the efficacy and safety of secukinumab, a fully human IgG1κ monoclonal anti-interleukin-17A antibody, in moderate-to-severe plaque psoriasis in a phase II regimen-finding study. Methods:  404 patients were randomised to subcutaneous placebo (67 patients) or one of three secukinumab 150 mg induction regimens: Single (week 0; 66 patients), Early (weeks 0, 1, 2, 4; 133 patients), and Monthly (weeks 0, 4, 8; 138 patients). The primary outcome was ≥75% improvement from baseline Psoriasis Area and Severity Index (PASI) score at week 12. PASI 75 responders from active treatment …

medicine.medical_specialtybusiness.industryDermatologyPlaceboSurgeryDiscontinuationlaw.inventionRegimenRandomized controlled trialMaintenance therapyPsoriasis Area and Severity IndexlawInternal medicinemedicineSecukinumabbusinessAdverse effectBritish Journal of Dermatology
researchProduct

Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.

2007

Proton pump inhibitors (PPIs) are antisecretory agents that are widely used in the short- and long-term management of gastroesophageal reflux disease (GERD) to relieve symptoms, heal esophagitis, and prevent complications, such as strictures and Barrett’s esophagus. The total healthcare costs of GERD are high, especially for maintenance treatment. Therefore, the choice of cost-effective therapeutic options is an ineluctable challenge for public health authorities, third-party payers, and patients. In some European Union countries, a recent trend of public health authorities is to promote the choice of less expensive PPIs, regardless of their antisecretory potency – this in spite of the evid…

medicine.medical_specialtybusiness.industryGastroenterologyRefluxAntisecretory agentsEsomeprazoleProton Pump InhibitorsDiseaseProton pump inhibitorGastroesophageal reflux diseasemedicine.diseaseGastroenterologydigestive system diseasesInternal medicineGERDmedicineGastroesophageal RefluxHumansbusinessEsophagitisTherapy optimizationRandomized Controlled Trials as TopicDigestion
researchProduct

Review of: "Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial"

2020

medicine.medical_specialtybusiness.industryGeneral EngineeringBone healingPlacebomedicine.diseaseSurgerylaw.inventionRandomized controlled triallawTeriparatidemedicinebusinessOsteonecrosis of the jawmedicine.drugQeios
researchProduct

Methodological matters on an Alzheimer's dementia trial: is a double-blind randomized controlled study design sufficient to draw strong conclusions o…

2007

medicine.medical_specialtybusiness.industryGinkgo bilobamedicine.diseaselaw.inventionDouble blindNeurologyRandomized controlled trialDouble-Blind MethodPiperidineslawAlzheimer DiseaseIndansmedicineDementiaHumansAlzheimer s dementiaDementiaDonepezilNeurology (clinical)Cholinesterase InhibitorsPsychiatrybusinessRandomized Controlled Trials as TopicEuropean journal of neurology
researchProduct

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Mul…

2019

Continuous treatment with lenalidomide (R) and dexamethasone (d) is a standard of care for multiple myeloma (MM) patients (pts) not candidates for autologous stem cell transplantation (ASCT). As previously reported, the addition of Clarithromycin (C) to Rd has proven to be safe and effective, and case-control analyses suggested a significant additive value with the combination. C optimizes the therapeutic effect of glucocorticoids by increasing the area under the curve, has immunomodulatory effects and may have direct antineoplastic properties. However, there are not randomized phase III trials confirming these results. GEM-Claridex in an open, randomized, phase III trial for untreated new…

medicine.medical_specialtybusiness.industryImmunologyDisease progressionCell BiologyHematologymedicine.diseaseBiochemistrylaw.inventionTransplantationClinical trialAutologous stem-cell transplantationRandomized controlled triallawInternal medicinemedicineIn patientbusinessMultiple myelomaLenalidomidemedicine.drugBlood
researchProduct

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial …

2008

Abstract We have previously reported that compared to CHOP alone the addition of Rituximab (R) to CHOP significantly increases the response rate (RR), the time to treatment failure (TTF) and also the overall survival (OS) in patients with newly diagnosed advanced follicular lymphoma. However, in the previous report, the median observation time was short with 18 months and no data were reported on the outcome of different risk groups according to the FLIPI (Hiddemann et al., Blood 2005). We now report on the treatment outcome of 552 patients with advanced stage follicular lymphoma randomized between R-CHOP versus CHOP alone after a median follow up of 58 months. Responding patients < …

medicine.medical_specialtybusiness.industryImmunologyFollicular lymphomaAlpha interferonCell BiologyHematologyCHOPDebulkingmedicine.diseaseBiochemistryChemotherapy regimenGastroenterologySurgerylaw.inventionRandomized controlled trialMedian follow-uplawInternal medicinemedicineRituximabbusinessmedicine.drugBlood
researchProduct

A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria

2016

medicine.medical_specialtybusiness.industryImmunologyQuilizumablaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemRandomized controlled trialRefractorylawInternal medicineImmunology and AllergyMedicinebusinessJournal of Allergy and Clinical Immunology
researchProduct

Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial C…

2020

Background Since the FDA approval of clofarabine for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) at childhood, several studies have been launched which put clofarabine under scrutiny in combination with other cytostatic drugs as second or third line therapy. As a novel treatment-strategy we introduced the combination of clofarabine with pegylated asparaginase (PEG-ASP) in a randomized fashion in comparison to the standard consolidation course with high dose cytarabine (Hidac) combined with PEG-ASP into the frontline management of ALL within the CoALL 08-09 protocol. The primary objective of the study was to compare the MRD based assessment of the cytotoxic eff…

medicine.medical_specialtybusiness.industryImmunologyUrologyCell BiologyHematologyBiochemistryMinimal residual diseaselaw.inventionHigh dose cytarabineRandomized controlled triallawmedicineClofarabinebusinessmedicine.drugBlood
researchProduct